Amarin Corporation(AMRN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For the fourth quarter of 2025, total net revenue was $49.2 million, down from $62.3 million in the same quarter of the previous year, reflecting a 21% decline [21] - U.S. sales declined by 7% due to a decrease in net selling price, driven by proactive pricing adjustments [21] - Total operating expenses decreased by 31%, or $13.5 million, with cost of goods sold declining by 63% [24] - The operating loss narrowed to $2.3 million from an operating loss of $16 million in the previous year's fourth quarter [26] - The company ended 2025 with $303 million in cash and investments, no debt, and working capital of $455 million [26] Business Line Data and Key Metrics Changes - Product revenue for Europe was $2.3 million, including $900,000 in supply shipments to Recordati, significantly lower than the $4 million of direct sales in Q4 2024 [22] - Rest of World revenues were $3.1 million, down from $11.9 million in the previous year's fourth quarter, impacted by $7.8 million in stocking orders in Q4 2024 [23] - SG&A expenses declined by 46%, representing 41% of total net sales compared to 59% in the previous year [25] Market Data and Key Metrics Changes - VASCEPA maintained clear market leadership in the U.S. across all available icosapent ethyl products, both branded and generic [7] - The company has established a partnership with Recordati to commercialize VAZKEPA across 59 countries, focusing on Europe, which is expected to enhance market access [9] Company Strategy and Development Direction - The company aims to transform its business model and expand the global market for its VASCEPA/VAZKEPA franchise through strategic partnerships and operational efficiencies [4] - The partnership with Recordati is expected to generate substantial economies of scale and significant revenue opportunities while providing extensive infrastructure [9] - The company is focused on maintaining exclusivity in the U.S. market and expanding its global presence through a partnered international commercial strategy [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of the VASCEPA franchise and its global growth potential, supported by a strong body of scientific evidence [6] - The company anticipates a pivotal year in 2026, focusing on defending its U.S. franchise and expanding its global presence [19] - Management highlighted the importance of proven therapies like VASCEPA in the evolving treatment landscape for cardiovascular disease [16] Other Important Information - The company achieved approximately half of the estimated $70 million in total operating expense savings from its global restructuring plan by the end of 2025 [5] - The company expects to incur the last of the restructuring expenses in early 2026 [25] Q&A Session Summary Question: Could you provide more color on the volume versus price dynamics in 4Q? - Management noted that volume and price remained consistent compared to Q3, with typical volume declines expected in Q1 [31][32] Question: How confident are you in sustaining exclusivity with your existing exclusive formulary in 2026? - Management expressed confidence in maintaining exclusivity through the year, citing past successes in regaining exclusives [37]